GlassScriptPhysician profile
Mary E Parker
NPI 1982795928
$12,229.57
in general payments reported to CMS, 2019-2025
14 companies · $4,922 in 2025
The $4,922 reported for 2025 was more than what 98% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $650 · 2022: $553 · 2023: $505 · 2024: $5,599 · 2025: $4,922.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,529 · Travel and Lodging: $3,928 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,320 · Consulting Fee: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,529.23 |
| Travel and Lodging | $3,927.54 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,320.00 |
| Consulting Fee | $250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $7,118.07 | 2021-2025 | Emblem Mri S-Icd, General - Therapies, Lux-Dx Insertable Cardiac Monitor |
| Medtronic, INC. | $2,586.06 | 2021-2025 | Linq II, Azure Xt Dr Mri Surescan, Cobalt Dr Mri Surescan |
| Biotronik INC. | $1,303.50 | 2021-2025 | Acticor 7 Vr-T Dx, Pamira, Renamic Neo |
| Impulse Dynamics (USA) INC. | $466.28 | 2024-2025 | Optimizer |
| Abbott Laboratories | $261.45 | 2021-2025 | Mitraclip, Aveir |
| Edwards Lifesciences Corporation | $172.59 | 2025 | Sapien 3 Ultra Resilia |
| Inspire Medical Systems, INC. | $101.65 | 2025 | Inspire |
| Convatec INC. | $60.00 | 2025 | |
| Scpharmaceuticals INC. | $39.65 | 2024 | |
| Biosense Webster, INC. | $31.38 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $29.78 | 2025 | Opsynvi, Uptravi |
| Merck Sharp & Dohme LLC | $20.26 | 2023 | Verquvo |
| Kiniksa Pharmaceuticals International, Plc | $20.11 | 2024 | Arcalyst |
| E.R. Squibb & Sons, L.L.C. | $18.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Parker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.